Article feed
-
Long-Acting Injectable Buprenorphine Treatment for Opioid Use Disorder Explained
Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST.
Read more -
-
-
Half a Million Reasons to Hope
As of April 2026, 500,000+ people have been prescribed our long-acting injectable buprenorphine treatment for OUD.
Read more -
VCU Research to Recovery 2026: Advancing Recovery through Community Connection
Indivior attends the VCU Research to Recovery 2026 conference. Bridging science, lived experience, and frontline practice, Research to Recovery brought together the people who make recovery happen every day: peer recovery specialists, community clinicians, family advocates, harm reductionists, and individuals in long-term recovery.
Read more -
